

## Forum Original Research Communication

# LMP2 Knock-Out Mice Have Reduced Proteasome Activities and Increased Levels of Oxidatively Damaged Proteins

QUNXING DING,<sup>1</sup> SARAH MARTIN,<sup>1</sup> EDGARDO DIMAYUGA,<sup>1</sup>  
ANNADORA J. BRUCE-KELLER,<sup>1</sup> and JEFFREY N. KELLER<sup>1,2</sup>

### ABSTRACT

The proteasome is a large intracellular protease, composed of multiple subunits, that is present in all eukaryotic cells. Proteasome inhibition is known to occur during normal aging, and is believed to contribute towards an age-related increase in oxidative stress, although at present the mechanisms responsible for mediating age-related changes in proteasome activity have not been elucidated. At present the relationship between proteasome subunit expression, proteasome activity, and protein oxidation during normal aging has not been elucidated. In the present study we observed that the absence of LMP2, a specific proteasome subunit, decreases proteasome activities in both the brain and liver, with increased levels of protein oxidation occurring in both tissues. Results from this study demonstrate for the first time that individual proteasome subunits are important for the regulation of age-related changes in both proteasome activity and protein oxidation. *Antioxid. Redox Signal.* 8, 130–135.

### INTRODUCTION

AS PART OF NORMAL AGING, as well as in a wide variety of age-related disorders, there is a well-documented increase in the level of protein oxidation (2, 19). Although the mechanisms responsible for mediating elevated levels of protein oxidation have not been elucidated, increasing evidence suggests that increased protein oxidation levels may play a causal role in promoting a variety of deleterious physiological disturbances observed in both normal aging and age-related disease (2, 19). The proteasome is a large intracellular protease that is composed of multiple subunits, possesses several proteolytic activities, and is responsible for mediating the degradation of a wide variety of intracellular protein substrates (3, 4). Numerous reports suggest that proteasome inhibition occurs in a variety of age-related disorders, as well as normal aging, with proteasome inhibition possibly playing a particularly important role in mediating increased levels of

protein oxidation (5, 6, 12, 13, 14, 17, 20, 22). At present the mechanism responsible for mediating proteasome inhibition in each of these conditions has not been elucidated.

In order to identify the contribution of individual proteasome subunits towards overall proteasome function, as well as general physiological and cellular homeostasis, a number of transgenic mice have been established and well characterized. One of the first mice generated for this purpose was the low molecular weight protein 2 knock-out mouse (LMP2 KO) (21). LMP2 is regarded as an inducible  $\beta$  subunit, and is thought to play an important role in the inducible- and immunology-related activities of proteasome (3, 4). Nearly all studies using transgenic mice deficient for individual proteasome subunits have focused on elucidating the role of individual proteasome subunits towards the regulation of immunological function, with no previous studies examining whether the absence of a single proteasome subunit has any effect on age-related impairment of proteasome function. Additionally, no previous study

---

<sup>1</sup>Department of Anatomy and Neurobiology, and <sup>2</sup>Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky.

has examined whether absence of a single proteasome subunit alters the level of protein oxidation in young or aging mice.

The focus of the present study was to determine if proteasome subunit expression becomes altered during normal aging, to determine the relationship between altered proteasome subunit expression and age-related declines in proteasome activity, to determine the relationship between age-related increases in protein oxidation and age-related proteasome inhibition, and to elucidate if the absence of an individual proteasome subunit (LMP2 subunit) alters any of these processes.

## MATERIALS AND METHODS

### *Transgenic mice*

Breeding pairs of LMP2 KO mice were a generous gift of Dr. L. Van Kaer (Vanderbilt University), and have been described extensively in previous studies (15, 16, 21). These mice were developed on a C57BL/6 background, with mice of this same background used as controls in all studies. All animals were maintained on a 12-hour light/dark cycle, and were maintained in a sterile pathogen-free environment, which was confirmed by the routine serological examination of sentinel mice in each room. A total of 8 wild-type mice and 8 LMP2 KO mice were utilized for each of the experimental conditions, in each of the biochemical assays reported. Tissues from each animal were harvested separately, and independent samples were used in all analyses. Only the brain and liver tissue were used in this study. Previous studies have documented that LMP2 KO mice appear normal, and possess no obvious health deficits up to 1 year of age (21).

### *Analysis of proteasome activity and proteasome expression*

Proteasome activity was determined as described previously (7–9, 18). Briefly, cell lysates were collected and protein aliquots (1 µg/µl) generated in proteasome activity buffer (10 mmol/L Tris-HCl, pH 7.8, 1 mmol/L EDTA, 0.5 mmol/L dithiothreitol, and 5 mmol/L MgCl<sub>2</sub>). Substrates specific for each of the proteasome proteolytic activities were added to proteasome activity buffer, and the cleavage of each of these peptides utilized to quantify the amount of proteasome activity. For analysis of 26S proteasome activity, 2 mM ATP was added to proteasome activity buffer. A standard curve of free 7-amido-4-methylcoumarin (MCA) was utilized for quantification of proteasome activity. Fluorescence was monitored at 340 nm excitation and 440 nm emission. Proteasome-mediated degradation of oxidized BSA was conducted using BODIPY labeled BSA (Molecular Probes, Carlsbad, CA), exactly as was reported previously for proteasome-mediated degradation casein (18), with the exception that BSA was mildly oxidized with FeSO<sub>4</sub> prior to analysis.

Proteasome subunit expression was quantified using a custom gene array, which utilizes membrane-bound gene-specific PCR products, ranging from 200 to 500 base pairs. The <sup>32</sup>P-labeled cDNA, derived from the retro-transcription of total RNA, was utilized as probe. A serial dilution of β-actin and 18S rRNA fragments was utilized for normalization and quantifi-

cation. Data was collected using a phosphoimager (Fuji, Stamford, CT) and quantified using NIH software (Scion Image, Frederick, MD). Each gene was analyzed in duplicate and normalized to β-actin expression. For each experimental time point and condition, data were obtained from eight separate mice. Data obtained from array studies was confirmed by conducting real time RT PCR for several of the proteasome subunit genes, as described previously from our laboratory (9).

### *Analysis of protein oxidation*

Protein oxidation was determined by analysis of protein carbonyl content as described previously (1, 10, 11), using the 2,4-dinitrophenylhydrazine (DNPH) procedure, which has been demonstrated previously to be a reliable and sensitive measure of protein oxidation. A 5% (weight/volume) tissue homogenate was prepared in TBS containing protease inhibitor cocktail (Sigma Chemical, St. Louis, MO) homogenized, and centrifuged at 700 × g. The resulting supernatant was treated with 10 mM DNPH dissolved in 2 N HCl, or with 2 N HCl alone in the controls. Samples were then incubated for 1 hour at room temperature, precipitated with 10% trichloroacetic acid, centrifuged for 3 minutes at 16,000 × g, and the resulting pellet washed three times with ethanol/ethyl acetate. The pellet was then redissolved in guanidine containing 10 mM phosphate buffer-trifluoroacetic acid (pH 2.3). The difference in absorbance between the DNPH-treated and the HCl-treated samples was determined at 366 nm, and the results expressed as nmol carbonyl groups/mg of protein using the extinction coefficient of 22.0 mmol<sup>-1</sup>cm<sup>-1</sup> for aliphatic hydrazones.

### *Statistical analysis*

Statistical significance was determined using a Student's *t*-test to do pairwise comparisons between two individual groups. Analysis was conducted using SigmaPlot software and *p* value of < 0.05 set for statistical significance.

## RESULTS

### *Proteasome activity*

In order to determine if proteasome subunit expression is altered during normal aging, we conducted studies in young (4-month-old) and aging (12-month-old) wild-type mice (C57BL/6). These studies revealed that the majority of proteasome subunits examined demonstrated a greater than 10% increase in expression with increased age, in the brain (15/21), with a smaller percentage of subunits increased in the liver (6/21) (Table 1). The alterations in proteasome subunit expression in the liver were markedly different from what is observed in the brain, suggesting that the alterations in proteasome expression observed during aging is tissue specific. Studies in transgenic mice that lacked functional LMP2 expression, LMP2 KO mice (11), revealed a nearly identical ratio of increased proteasome subunit expression during normal aging of both the brain and liver (Table 1), as compared to wild-type mice.

We next examined proteasome activity in the brain and liver of aging wild-type and LMP2 KO mice. Analysis of 20S proteasome function in the brain and liver of young mice revealed

TABLE 1. ALTERATIONS IN PROTEASOME SUBUNIT EXPRESSION IN BRAINS AND LIVER OF AGING CONTROL AND MUTANT MICE

|               |                 | BRAIN                             |   | LIVER                             |   |
|---------------|-----------------|-----------------------------------|---|-----------------------------------|---|
|               |                 | Wild type<br>(ratio 12 mos/4 mos) | LMP2 <sup>-/-</sup><br>(ratio 12 mos/4 mos) | Wild type<br>(ratio 12 mos/4 mos) | LMP2 <sup>-/-</sup><br>(ratio 12 mos/4 mos) |
| b1            | (20S $\alpha$ ) | 1.56                              | 1.55  | 0.89                              | 1.10  |
| b2            | (20S $\alpha$ ) | 1.07                              | 1.12  | 1.33                              | 1.30  |
| C2            | (20S $\alpha$ ) | 1.13 (2.29)                       | 1.14 (1.01)                                 | 1.20 (2.48)                       | 0.60 (0.70)                                 |
| C8            | (20S $\alpha$ ) | 1.36                              | 1.37  | 1.18                              | 1.09  |
| C9            | (20S $\alpha$ ) | 1.29                              | 1.03  | 1.22                              | 1.40  |
| C10           | (20S $\alpha$ ) | 1.26                              | 1.09  | 1.24                              | 0.82  |
| PRE1          | (20S $\alpha$ ) | 1.74                              | 1.32  | 0.89                              | 0.94  |
| C5            | (20S $\beta$ )  | 1.12                              | 1.06  | 1.03                              | 0.96  |
| MB1           | (20S $\beta$ )  | 0.76                              | 1.09  | 0.91                              | 0.76  |
| LMP2          | (20S $\beta$ )  | 1.12                              | NA  | 1.01                              | NA  |
| LMP7          | (20S $\beta$ )  | 1.01                              | 1.33  | 0.92                              | 1.24  |
| LMP10         | (20S $\beta$ )  | 1.09 (1.06)                       | 0.99 (0.98)                                 | 0.95 (0.69)                       | 1.58 (1.20)                                 |
| PRE4          | (20S $\beta$ )  | 1.17                              | 1.18  | 1.06                              | 1.97  |
| S1            | (19S)           | 1.31                              | 1.14  | 0.94                              | 1.17  |
| S4            | (19S)           | 1.20                              | 1.14  | 1.07                              | 1.36  |
| S9            | (19S)           | 1.15                              | 1.04  | 1.01                              | 0.90  |
| S11           | (19S)           | 1.08                              | 1.20  | 1.39                              | 0.54  |
| S12           | (19S)           | 1.23                              | 1.20  | 0.99                              | 1.20  |
| p28           | (19S)           | 1.22                              | 1.15  | 1.02                              | 1.60  |
| PA28 $\alpha$ | (11S)           | 1.19 (1.10)                       | 1.11 (1.02)                                 | 0.98 (0.88)                       | 1.14 (1.06)                                 |
| PA28 $\beta$  | (11S)           | 0.99                              | 1.66  | 1.04                              | 0.52  |

Expression of individual proteasome subunits was determined using a custom proteasome subunit expression array designed to quantify the expression for the indicated proteasome subunit at the level of RNA. The expression of each gene was normalized to  $\beta$ -actin expression, and the mean value of expression for each individual gene calculated from 8 separate experiments. Data are expressed as the ratio of the means for the indicated experimental conditions. Real time RT PCR analysis was utilized to confirm data obtained from custom proteasome subunit expression array, and is presented in parenthesis.

that LMP2 KO mice had significantly lower chymotrypsin-like activity in the brain, as compared to young wild type mice (Fig. 1A). Within the liver of young LMP2 KO mice there was a significant decrease in all 20S proteolytic activities of the proteasome (Fig. 1B), as compared to young wild-type mice. In both the brain and liver, young LMP2 KO mice demonstrated a significant decrease in chymotrypsin-like and post-glutamyl peptidase activities of the 26S proteasome (Figs. 1C and 1D) as compared to young wild-type mice. In aging wild-type mice, the only significant decreases in any individual proteasome activity consisted of a impairment in 26S chymotrypsin-like activity in the brain and 26S post-glutamyl peptidase activity in the liver (Figs. 1C and 1D). In LMP2 KO mice there were significant age-related impairment in multiple activities of the 20S and 26S proteasome, which were evident in both the liver and the brain (Figs. 1A–D). The ability of proteasome to degrade mildly oxidized protein was impaired in the liver, but not the brain, of aging wild-type mice (Figs. 1E and 1F). In LMP2 KO mice there was a significant age-related decrease in proteasome mediated degradation of mildly oxidized protein in both the liver and brain (Figs. 1E and 1F). In most cells both the 20S and 26S proteasome complexes are present, and with each enzyme mediating different functions. In general, the activities of 26S proteasome are highly ATP dependent, primarily degrade ubiquitinated proteins, and are therefore under


the regulation of all proteins involved in regulating ubiquitin-mediated proteolysis. On the other hand, the 20S proteasome is ATP independent, and primarily degrades proteins independent of ubiquitination. In light of this it is quite expected that the 20S and 26S should show a different response to aging and the stress associated with the loss of LMP2 expression.

### Protein oxidation

Analysis of protein oxidation, via quantification of protein carbonyl levels, revealed that young LMP2 KO mice exhibited higher levels of protein oxidation in both the brain and liver (Figs. 2A and 2B), as compared to wild-type mice. Aging wild-type mice exhibited increased levels of oxidized protein in both the brain and liver (Figs. 2A and 2B), as compared to 4-month-old mice. LMP2 KO mice demonstrated an age-related increase in oxidized protein levels in both the brain and liver (Figs. 2A and 2B), with the brain exhibiting higher levels of oxidized protein than age-matched wild-type mice (Fig. 2A).

## DISCUSSION


In the present study both the brain and liver exhibited age-related increases in proteasome subunit expression. Within



**FIG. 1. Role of LMP2 in age-related alterations in proteasome activity.** The chymotrypsin-like, trypsin-like, and post-glutamyl peptidase activities of the 20S and 26S proteasome were determined in the brain (A, C) and liver (B, D). Proteasome activity was analyzed in the brain and liver of young (4-month-old) and aging (12-month-old) LMP2 KO mice (KO), and nontransgenic wild-type mice (WT). The ability of the proteasome to degrade mildly oxidized bovine serum albumin (oxBSA) was determined in the brain (E) and liver (F) of young and aging KO or WT mice. All data are expressed as the mean and SEM of results from 16 young (8 WT/8 KO) and 16 aging mice (8 WT/8 KO). \* $p < 0.01$  compared to age-matched animal of same background; \*\* $p < 0.01$  compared to 4-month-old mice; \*\*\* $p < 0.03$  compared to 4-month-old animal and age-matched animal of different background.

the brain, a higher percentage of proteasome subunits exhibited increased expression with age, as compared to the liver. These data suggest a potentially important role for proteasome subunit plasticity in maintaining proteasome function during normal aging, and may indicate that a plasticity in proteasome subunit expression is particularly important in the brain.

No significant decreases in 20S proteasome activity was observed in either the brain or liver of aging wild-type mice, even though slight impairments in individual 26S proteasome activities were observed in both the brain and liver. A significant age-related impairment in proteasome-mediated degradation of oxidized protein was observed in the liver of wild-



**FIG. 2. Role of LMP2 in age-related alterations in protein oxidation.** The amount of protein oxidation (protein carbonyls) was quantified in the brain (E) and liver (F) of young (4-month-old) and aging (12-month-old) LMP2 KO mice (KO), and nontransgenic wild type mice (WT). All data are expressed as the mean and SEM of results from 16 young (8 WT/8 KO) and 16 aging mice (8 WT/8 KO). \* $p < 0.01$  compared to age-matched animal of same background; \*\* $p < 0.01$  compared to 4-month-old mice; \*\*\* $p < 0.03$  compared to 4-month-old animal and age-matched animal of different background.

type mice, with both the brain and liver exhibiting an age-related increase in oxidized protein levels. Taken together, these data may indicate that the 26S proteasome is more vulnerable to age-related inhibition, and suggest that the ability of the proteasome to degrade oxidized protein may be regulated by factors other than the maintaining individual proteasome proteolytic activities. Data also indicate that the initial age-related elevations in oxidized protein levels are mediated by factors other than gross proteasome inhibition.

LMP2 KO mice demonstrated a more robust age-related inhibition of individual proteasome proteolytic activities, as well as impairments in proteasome-mediated degradation of oxidized protein. Interestingly, age-related impairments in both 20S and 26S proteasome function were observed, with both evident in both the brain and liver of LMP2 KO mice. In the brain, but not the liver, this inhibition was associated with a significant exacerbation of age-related increases in oxidized protein levels. These data suggest that losing the expression of a single proteasome subunit can result in gross changes in proteasome function. Additionally, our data indicate that these changes in proteasome function are exacerbated during normal aging, and may result in an elevated level of protein oxidation.

Cumulatively, our data suggest that proteasome subunit expression is altered during normal aging, with increased expres-

sion of multiple proteasome subunits possibly playing an important role in preserving proteasome function during normal aging. In the present study, the absence of a single proteasome subunit resulted in a more robust age-related impairment in proteasome activity, and age-related elevation in oxidized protein levels. Such observations highlight the potential adaptability of the proteasome, and suggest that the proteasome attempts to respond to age-related stressors by increasing proteasome subunit expression in order to maintain proteasome function. The maintenance of proteasome activity appears to be particularly important for preventing the secondary, but not initial, age-related increase in oxidized protein levels. Many factors are involved in initiating the increased oxidative damage observed in aging tissues, with increased free radical generation being an important mediator of oxidative damage. Consistent with these observations, recent studies have demonstrated the ability of low-level oxidative stress to increase proteasome subunit expression in neural cells, which was associated with a preservation of proteasome activity and only slight increases in oxidized protein levels (9, 12, 22).

In future studies it will be critical to elucidate fully the subtle nuances of proteasome subunit expression, developing a firm understanding of what causes age-related alterations in proteasome subunit expression, and elucidating mechanisms which serve to maintain proteasome activity throughout the aging process. Such interventions may lead to more successful aging and thus provide a therapeutic benefit to a host of age-related diseases.

## ABBREVIATIONS

ATP, adenosine triphosphate; BSA, bovine serum albumin; DNPH, 2,4-dinitrophenylhydrazine; EDTA, ethylenediaminetetraacetic acid; HCl, hydrochloric acid; LMP, latent membrane protein.

## ACKNOWLEDGMENTS

The authors wish to thank Jillian Gee for editorial assistance, Dr. L. Van Kaer for the initial LMP2 KO breeding pairs, and Dr. William R. Markesbery for his continual support. The present work was supported by grants from the National Institutes of Health [AG018437 (JNK), AG005119 (JNK)].

## REFERENCES

1. Agarwal S and Sohal RS. Differential oxidative damage to mitochondrial proteins during aging. *Mech Aging Dev* 85: 55–63, 1995.
2. Berlett BS and Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem* 272: 20313–20316, 1997.
3. Bochtler M, Ditzel L, Groll M, Hartmann C, and Huber R. The proteasome. *Annu Rev Biophys Biomol Struct* 28: 295–317, 1999.
4. Coux O, Tanaka K, and Goldberg AL. Structure and functions of the 20S and 26S proteasomes. *Annu Rev Biochem* 65: 801–847, 1996.

5. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. *Biochimie* 83: 301–310, 2001.
6. Ding Q and Keller JN. Proteasomes and proteasome inhibition in the central nervous system. *Free Radic Biol Med* 31: 574–584, 2001.
7. Ding Q and Keller JN. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. *J Neurochem* 77: 1010–1017, 2001.
8. Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC, and Keller JN. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. *J Biol Chem* 277: 13935–13942, 2002.
9. Ding Q, Reinacker K, Dimayuga E, Nukala V, Drake J, Butterfield DA, Dunn JC, Martin S, Bruce-Keller AJ, and Keller JN. Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. *FEBS Lett* 546: 228–232, 2003.
10. Dubey A, Forster MJ, Lal H, and Sohal RS. Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. *Arch Biochem Biophys* 333: 189–197, 1996.
11. Forster MJ, Sohal BH, and Sohal RS. Reversible effects of long-term caloric restriction on protein oxidative damage. *J Gerontol A Biol Sci Med Sci* 55: B522–B529, 2000.
12. Grune T. Oxidative stress, aging and the proteasomal system. *Biogerontology* 1: 31–40, 2000.
13. Grune T and Davies KJ. Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. *Biofactors* 6: 165–172, 2000.
14. Grune T, Merker K, Sandig G, and Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. *Biochem Biophys Res Commun* 305: 709–718, 2003.
15. Hayashi T and Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knock-out mice. *Cancer Res* 62: 24–27, 2002.
16. Johnsen AK, France J, Nagy N, Askew D, Abdul-Karim FW, Gerson SL, Sy MS, and Harding CV. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. *Int J Cancer* 91: 366–372, 2001.
17. Keller JN, Gee J, and Ding Q. The proteasome in brain aging. *Ageing Res Rev* 1: 279–293, 2002.
18. Louie JL, Kapphahn RJ, and Ferrington DA. Proteasome function and protein oxidation in the aged retina. *Exp Eye Res* 75: 271–284, 2002.
19. Sohal RS. Role of oxidative stress and protein oxidation in the aging process. *Free Radic Biol Med* 33: 37–44, 2002.
20. Szwed PA, Friguet B, and Szwed LI. Proteolysis, free radicals, and aging. *Free Radic Biol Med* 33: 29–36, 2002.
21. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, and Tonegawa S. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. *Immunity* 1: 533–541, 1994.
22. Ward WF. The relentless effects of the aging process on protein turnover. *Biogerontology* 1: 195–199, 2000.

Address reprint requests to:

Jeffrey N. Keller

Departments of Anatomy and Neurobiology

and Sanders-Brown Center on Aging

University of Kentucky

Lexington, KY 40536

E-mail: Jnkell0@email.uky.edu

Received for publication July 26, 2005; accepted August 2, 2005.



**This article has been cited by:**

1. Frédéric Ebstein, Peter-Michael Kloetzel, Elke Krüger, Ulrike Seifert. 2012. Emerging roles of immunoproteasomes beyond MHC class I antigen processing. *Cellular and Molecular Life Sciences* **69**:15, 2543-2558. [[CrossRef](#)]
2. Deborah A. Ferrington, Dale S. Gregerson. Immunoproteasomes **109**, 75-112. [[CrossRef](#)]
3. Nathalie Vigneron, Benoît J Van den Eynde. 2011. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. *Current Opinion in Immunology* . [[CrossRef](#)]
4. L. Henry, L. Le Gallic, G. Garcin, O. Coux, N. Jumez, P. Roger, T. Lavabre-Bertrand, J. Martinez, L. Meunier, P.E. Stoeber. 2011. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin. *British Journal of Dermatology* no-no. [[CrossRef](#)]
5. B. Guillaume, J. Chapiro, V. Stroobant, D. Colau, B. Van Holle, G. Parvizi, M.-P. Bousquet-Dubouch, I. Theate, N. Parmentier, B. J. Van den Eynde. 2010. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. *Proceedings of the National Academy of Sciences* **107**:43, 18599-18604. [[CrossRef](#)]
6. Christopher D. Morrison, Paul J. Pistell, Donald K. Ingram, William D. Johnson, Ying Liu, Sun Ok Fernandez-Kim, Christy L. White, Megan N. Purpera, Romina M. Uranga, Annadora J. Bruce-Keller, Jeffrey N. Keller. 2010. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. *Journal of Neurochemistry* **114**:6, 1581-1589. [[CrossRef](#)]
7. Hyun Kyoung Lee, Lih Wang, Yoon Kyung Shin, Kyu Yeol Lee, Duk Joon Suh, Hwan Tae Park. 2009. Interleukin-6 induces proinflammatory signaling in Schwann cells: A high-throughput analysis. *Biochemical and Biophysical Research Communications* **382**:2, 410-414. [[CrossRef](#)]
8. Deborah A. Ferrington, Stacy A. Hussong, Heidi Roehrich, Rebecca J. Kappahn, Shannon M. Kavanaugh, Neal D. Heuss, Dale S. Gregerson. 2008. Immunoproteasome responds to injury in the retina and brain. *Journal of Neurochemistry* **106**:1, 158-169. [[CrossRef](#)]
9. Paula van Tijn, Elly M. Hol, Fred W. van Leeuwen, David F. Fischer. 2008. The neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype. *Progress in Neurobiology* **85**:2, 176-193. [[CrossRef](#)]
10. Cheryl M. Ethen, Stacy A. Hussong, Cavan Reilly, Xiao Feng, Timothy W. Olsen, Deborah A. Ferrington. 2007. Transformation of the proteasome with age-related macular degeneration. *FEBS Letters* **581**:5, 885-890. [[CrossRef](#)]
11. B. Halliwell . 2006. Proteasomal Dysfunction: A Common Feature of Neurodegenerative Diseases? Implications for the Environmental Origins of Neurodegeneration. *Antioxidants & Redox Signaling* **8**:11-12, 2007-2019. [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
12. Dr. Jeffrey N. Keller . 2006. The Many Nuances of Oxidative Stress and Proteolysis. *Antioxidants & Redox Signaling* **8**:1-2, 119-120. [[Citation](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]